NCT06560606 UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
| NCT ID | NCT06560606 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hospital for Sick Children |
| Condition | Juvenile Idiopathic Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,100 participants |
| Start Date | 2018-08-24 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,100 participants in total. It began in 2018-08-24 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.
Eligibility Criteria
Inclusion Criteria: Cohort 1: - Biologic Basis of JIA * ≤18 years\* * Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment * Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis Cohort 2 - Start Biologics * JIA diagnosis as per ILAR criteria (all subtypes) * ≤18 years\* * Active arthritis * For sJIA, active disease not necessarily with arthritis. * Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance Cohort 3 - Stop Biologics * JIA diagnosis as per ILAR criteria (all subtypes) * ≤18 years\* * Inactive disease * Discontinuing/tapering biologics for inactive disease Cohort 4: Extreme Phenotypes * Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations * High suspicion of genetic contribution * Severely affected patients with difficult to control disease (ie failure of multiple biologics) Exclusion Criteria: Cohort 1 : * Arthritis explained by another diagnosis * Joint injections as previous treatment less than 4 weeks prior to enrollment Cohort 2: * Arthritis explained by any other cause * Start on biologics as an indication for uveitis only Cohort 3: \- Tapering scheme \> 12 months to complete biologics stop Cohort 4: \- Arthritis explained by another diagnosis
Contact & Investigator
Rae SM Yeung, MD, PhD, FRCPC
PRINCIPAL INVESTIGATOR
The Hospital for Sick Children (SickKids), University of Toronto
Frequently Asked Questions
Who can join the NCT06560606 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Juvenile Idiopathic Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06560606 currently recruiting?
Yes, NCT06560606 is actively recruiting participants. Contact the research team at alexander.mosiu@sickkids.ca for enrollment information.
Where is the NCT06560606 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, Vancouver, Canada, Winnipeg, Canada and 11 additional locations.
Who is sponsoring the NCT06560606 clinical trial?
NCT06560606 is sponsored by The Hospital for Sick Children. The principal investigator is Rae SM Yeung, MD, PhD, FRCPC at The Hospital for Sick Children (SickKids), University of Toronto. The trial plans to enroll 4,100 participants.